Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21Waf1/Cip1 and p27Kip1

• DOI: 10.1016/j.tjog.2016.09.003
• Publication Date: 2016-12-28T16:31:11Z
• Authors: Yuanyuan Zhou; Ke Wang; Shuai Zhen; Ruili Wang; Wenjuan Luo
• Keywords: HeLa; Viability assay; G1 phase

Carfilzomib is a second-generation tetrapeptide epoxyketone proteasome inhibitor used in current clinical therapy of hematologic malignancies. The mechanism inhibition endometrial cancer not very clear. type I carcinoma cell proliferation by inducing cycle arrest at the G2/M phase was investigated our study.HEC-1-A and Ishikawa lines three tumor were treated different concentrations carfilzomib. Methyl thiazolyl tetrazolium (MTT) assay to detect viability. Flow cytometry analyze cycle. Western blot proteins involved progression.Carfilzomib impaired viability myelogenous leukemia line K562, cervical HeLa, hepatocellular SMCC-7721, HEC-1-A Ishikawa. arrested carfilzomib-treated cells, while it both S phases cells. treatment significantly induced p21Waf1/ Cip1 p27, substantially reduced cyclin D3 cyclin-dependent kinase 1.This study showed that carfilzomib inhibited upregulating inhibitors p21Waf1/Cip1 p27Kip1, reducing 1 phase.